A major cancer research project in memory of singer Sarah Harding will look for early signs of breast cancer in young women.

Ms Harding, who was part of the pop group Girls Aloud, died from the disease aged 39 in 2021. One of her final wishes was to find new ways of spotting breast cancer early, when it is more treatable.

The new Breast Cancer Risk Assessment in Young Women (Bcan-Ray) project will become one of the first in the world to identify which women are at risk of getting the disease in their 30s.

Around 2,300 women aged 39 and under are diagnosed with breast cancer in the UK each year.

The project, which will run in Greater Manchester, is being made possible thanks to funding from the Christie Charity, Cancer Research UK and the Sarah Harding Breast Cancer Appeal, which is supported by Harding’s family, friends and Girls Aloud bandmates Cheryl Tweedy, Kimberley Walsh, Nadine Coyle and Nicola Roberts.

Speaking about the study before her death in comments shared exclusively with the PA, Ms Harding said: ‘Research is incredibly important in the fight against cancer.

‘Although this research may not be in time to help me, this project is incredibly close to my heart as it may help women like me in the future.’

Ms Harding was treated at the Christie cancer hospital in Manchester.

Catherine Craven-Howe, 33, from Hale in south Manchester, is the first person to take part in the new trial.

She is studying medicine at Liverpool University while working as a healthcare assistant in an eating disorders unit.

Her first appointment included a low dose mammogram to assess her breast density and a saliva sample for genetic testing.

‘Although I don’t have breast cancer myself and I don’t have a history of it in my family, I know just how important clinical trials and research are,’ said Ms Craven-Howe.

‘I hope my participation will help devise a simple test to detect the likelihood of breast cancer for young women like me in the future.’

Eight to 10 weeks after her appointment, Ms Craven-Howe will receive feedback about her risk of breast cancer.

Later, she will undertake a psychological impact questionnaire and receive a breast cancer risk statement at end of the study, likely to be in 2025.

The project aims to examine the risk factors most commonly found in women diagnosed with breast cancer in their 30s with the hope of building a model to identify these women in the future.

Researchers hope their findings will enable all women to have a risk assessment for breast cancer when they reach the age of 30, with those deemed high risk given access to early screening and opportunities to prevent cancer developing.

The study will recruit 1,000 women aged between 30 and 39, including 250 with breast cancer but no family history of the disease.

The saliva samples will also help experts from the Christie and Cancer Research UK establish which types and patterns of genes are implicated in cancer, with a view to developing personalised risk scores.

These can be combined with other breast cancer risk factors such as when a woman’s periods started, alcohol intake and use of the contraceptive pill.

The density of breast tissue may also play a part in the level of risk of getting the disease.

Ms Harding’s consultant, Dr Sacha Howell, who is leading the Bcan-Ray study, said: ‘Sarah spoke to me many times about breast cancer research and was really keen for more to be done to find out why young women are being diagnosed without any other family members having been affected by the disease.

‘There are too many young women in their 30s like Sarah tragically dying from breast cancer and we need to find out how we can more accurately identify those in whom it will develop.

‘Currently the only indicator we have is based on family history, but this only helps predict one third of cases. While there is research available in the over 40s, this will be the first study in young women.

‘With breast cancer still the leading cause of death in women under 50, we need to find ways to identify those most at risk and offer them breast screening to detect cancers earlier, when treatment is more likely to be successful.’

Michelle Mitchell, chief executive of Cancer Research UK, said: ‘Even in the darkest days of her cancer journey, Sarah Harding was a fearless advocate for research.

‘She bravely faced up to the pain the cancer caused her, undergoing treatment while thinking of ways to help other women in a similar position.

‘Since Sarah’s death, it has been inspiring to see people coming together in her memory to support life-saving research. The money raised in Sarah’s name will go a long way towards diagnosing breast cancer earlier in younger women.

‘The Bcan-Ray project will fulfil Sarah’s dying wish to help women like her. By harnessing the power of cutting-edge science, we can look forward to the day where all women can live free from the fear of breast cancer.’

Source: Read Full Article